Continuous Infusion Versus Intermittent IV Bolus of Cefazolin: Prevention of Surgical Site Infect… (NCT07658378) | Clinical Trial Compass
Not Yet RecruitingPhase 4
Continuous Infusion Versus Intermittent IV Bolus of Cefazolin: Prevention of Surgical Site Infection During CABG Surgeries in Egyptian Patients.
100 participantsStarted 2026-07-01
Plain-language summary
A randomized controlled trial on adults who underwent coronary artery bypass grafting (CABG) surgery. To evaluate the effectiveness of intraoperative continuous infusion (CI) of cefazolin compared with intermittent (INT) cefazolin administration in preventing surgical site infection in the CABG population.
Eligible patients will be randomized using a block design into 2 groups: intervention and control. The intervention group will use continuous infusion of cefazolin (CI), while the control group will follow the traditional presurgical prophylaxis protocol of intermittent cefazolin doses (INT).
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Cardiothoracic ICU-admitted patients who underwent CABG on CPB.
Exclusion Criteria:
* Patients who require reoperation within 30 days.
* Immunosuppressant patients.
* Patients who are not adherent to the protocol time or dosing, either preoperatively, during, or postoperatively.
* Pregnancy or breastfeeding.
* Patients who refused to sign the informed consent.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is comparing two ways of giving cefazolin — a continuous drip versus separate bolus doses — to prevent infection after CABG heart surgery, so could you explain which method you currently use for my surgery and whether either approach might be more appropriate for my situation?
2Since this trial is in Phase 4, does that mean cefazolin itself is already well-established and the main question here is just about the best way to deliver it, and how does that affect what's still unknown about risks?
3The trial hasn't started recruiting yet — does that mean if I'm interested, we'd need to wait, and would standard antibiotic prevention during my CABG surgery in the meantime already cover me adequately?
4The trial is focused specifically on Egyptian patients undergoing CABG — given that patient population focus, is this study likely to be relevant to my own background, health profile, or the hospital where I'd be treated?
5If the primary goal is reducing surgical site infections after CABG, are there other proven steps or protocols already in place at your facility that address this risk, and how would participating in this trial compare to what I'd receive as standard care?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.